JYNNEOS OFFERED STRONG PROTECTION AGAINST MPOX INFECTION 

Vaccination with the Jynneos smallpox vaccine was found to offer strong protection against mpox infection after one or two doses, according to a study conducted by the Centers for Disease Control and Prevention (CDC), providing some of the first clinical evidence on the efficacy of the shot used to fight back against the mpox outbreak this year.

• New data released in the CDC’s Morbidity and Mortality Weekly Report found that the incidence of mpox infections among unvaccinated people was nearly 10 times higher when compared to the incidence rate among fully vaccinated individuals, and 7.4 times higher when compared to those who had received only one dose.
• The CDC acknowledged that more data was still needed to fully determine the impact of Jynneos against mpox, which was formerly known as monkeypox, but stated that this study indicated the drug’s efficacy.

The CDC noted in its weekly report that the analysis of cases did not suggest a difference in protection between intradermal shots and subcutaneous ones, which are administered into the muscle and include a full dose of the vaccine like most other immunization injections.